Upadacitinib
Generic name: Upadacitinib
Brand names: Rinvoq
Drug class:
Antirheumatics
Usage of Upadacitinib
Upadacitinib is used alone or with other medications to treat rheumatoid arthritis (a condition in which the body attacks its own joints causing pain, swelling, and loss of function) in people who are unable to take or have not responded well to one or more tumor necrosis factor (TNF) inhibitor medication(s).
Upadacitinib is also used to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin) in adults who are unable to take or did not respond to or tolerate one or more TNF inhibitor medication(s).
Upadacitinib is also used to treat symptoms of eczema (atopic dermatitis; a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes) in adults and children 12 years and older who cannot use other medications for their condition or whose eczema has not responded to other medications.
Upadacitinib is also used to treat ulcerative colitis (a condition that causes swelling and sores in the lining of the colon [large intestine] and rectum) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s).
Upadacitinib is also used to treat Crohn's disease (a condition in which the body attacks the lining of the digestive tract, causing pain, diarrhea, weight loss, and fever) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s).
Upadacitinib is used to treat ankylosing spondylitis (a condition in which the body attacks the joints of the spine and other areas, causing pain, swelling, and joint damage) in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s).
Upadacitinib is also used to treat active non-radiographic axial spondyloarthritis (a condition in which the body attacks the joints of the spine and other areas, causing pain and signs of swelling), but without changes seen on X-ray, in adults who are unable to take or who did not respond to one or more TNF inhibitor medication(s).
Upadacitinib belongs to a class of medications called Janus kinase (JAK) inhibitors. It works by decreasing the activity of the immune system.
Upadacitinib side effects
Get emergency medical help if you have signs of an allergic Reaction to upadacitinib: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Upadacitinib affects your immune system, and may cause certain white blood cells to grow out of control. Call your doctor right away if you have:
Some people taking upadacitinib have developed heart attacks, strokes, or serious blood clots. Seek emergency medical attention if you have:
upadacitinib may cause serious side effects. Call your doctor at once if you have:
Your treatment may be delayed or permanently discontinued if you have certain side effects.
Common upadacitinib side effects may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Upadacitinib
You should not take this medicine if you are allergic to upadacitinib.
Before you start taking upadacitinib, tell your doctor if you have any signs of infection such as fever, sweating, chills, cough, body aches, tiredness, open sores or skin wounds, shortness of breath, diarrhea, stomach pain, weight loss, painful urination, or coughing up blood.
To make sure upadacitinib is safe for you, tell your doctor if you have ever had:
Make sure you are current on all vaccines before you start using upadacitinib.
Using upadacitinib may increase your risk of developing certain cancers, such as lymphoma, lung cancer or skin cancer. Ask your doctor about this risk.
You may need to have a negative pregnancy test before starting this treatment.
May harm an unborn baby. Use effective birth control while using upadacitinib and for at least 4 weeks after your last dose. Tell your doctor if you become pregnant.
Do not breastfeed while using upadacitinib, and for at least 6 days after your last dose.
Relate drugs
- Apremilast
- Auranofin
- Cuprimine
- Depen
- D-Penamine
- Otezla
- Penicillamine
- Ridaura
- Rinvoq
- Tofacitinib
- Upadacitinib
- Xeljanz
How to use Upadacitinib
Usual Adult Dose of Upadacitinib for Rheumatoid Arthritis:
15 mg orally once a day Comments: -This drug may be used as monotherapy or in combination with methotrexate or other nonbiologic disease modifying antirheumatic drugs (DMARDs). -This drug is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells/mm3, absolute Neutrophil count (ANC) less than 1000 cells/mm3, or hemoglobin level less than 8 g/dL. -Limitations of use: This drug is not recommended in combination with other Janus kinase (JAK) inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. Use: Treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
Usual Adult Dose of Upadacitinib for Psoriatic Arthritis:
15 mg orally once daily Comments: -Limitations of use: Not recommended to use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. Use: Adults with active psoriatic arthritis with inadequate response or intolerance to TNF blockers
Usual Adult Dose for Atopic Dermatitis:
Initiation dose: 15 mg orally once daily Maximum dose: 30 mg orally once daily (if no response with initial dose) Duration of therapy: Discontinue if no response is achieved with 30 mg/day dose.
Usual Geriatric Dose for Atopic Dermatitis:
Adults 65 years of age and older: 15 mg orally once daily.
Usual Pediatric Dose for Atopic Dermatitis:
Patients 12 years of age and older weighing at least 40 kg: Initiation dose: 15 mg orally once daily Maintenance dose: 30 mg orally once daily (if no response with initial dose) Maximum dose: 30 mg orally once daily Duration of therapy: Discontinue if no response is achieved with 30 mg dose Comments: -Use the lowest dose to maintain response -Limitations of use: Not recommended to use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants Use: Pediatric patients older than 12 years old and weighing at least 40 kg with refractory, moderate to severe atopic dermatitis that has not been adequately controlled with other systemic drug products, including biologics, or when other therapies are inadvisable
Warnings
Taking upadacitinib may increase your risk of life-threatening medical problems including serious infections, a hole or tear in your digestive tract, a heart attack or stroke, blood clots, or cancer.
Call your doctor right away if you have a fever, night sweats, constant tiredness, weight loss, stomach pain, diarrhea or changes in bowel habits, trouble breathing, wheezing, a severe cough, or lumps in your neck, armpits, or groin.
Seek emergency medical attention if you have sudden shortness of breath, chest pain spreading to your neck or arms, nausea, severe dizziness, a cold sweat, weakness on one side of your body, slurred speech, or pain, redness, or swelling in an arm or leg.
If you've had hepatitis B, it may come back or get worse. Tell your doctor if you don't feel well and you have right-sided upper stomach pain, vomiting, loss of appetite, or yellowing of your skin or eyes.
What other drugs will affect Upadacitinib
Sometimes it is not safe to use certain medicines at the SAMe time. Some drugs can affect your blood levels of other drugs you use, which may increase side effects or make the medicines less effective.
Tell your doctor about all your current medicines. Many drugs can affect upadacitinib, especially:
This list is not complete and many other drugs may interact with upadacitinib. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible drug interactions are listed here.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions